<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02396862</url>
  </required_header>
  <id_info>
    <org_study_id>17285</org_study_id>
    <secondary_id>KG1301</secondary_id>
    <nct_id>NCT02396862</nct_id>
  </id_info>
  <brief_title>Patient Functioning and Well-being, Economic, and Clinical Impact of Hemophilia A and Its Treatment</brief_title>
  <acronym>ECHO</acronym>
  <official_title>A Prospective, International, Longitudinal, Observational Disease Registry of Patient-reported Outcomes (PROs) and the Association With Hemophilia A and Its Treatment in Patients With Moderate to Severe Hemophilia A</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to improve the understanding of key patient reported outcomes
      such as quality of life as well as clinical outcomes in hemophilia A, in a global real world
      setting.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 9, 2015</start_date>
  <completion_date type="Actual">March 26, 2018</completion_date>
  <primary_completion_date type="Actual">January 17, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Patient Reported Outcome: Change of function as measured by Hemophilia Activities List (HAL), Daily Activities including Work Productivity and Activity Impairment Scale (WPAI).</measure>
    <time_frame>Baseline and at 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Reported Outcome: Change of function as measured by Hemophilia Activities List (HAL), Daily Activities including Work Productivity and Activity Impairment Scale (WPAI).</measure>
    <time_frame>Baseline and at 24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Reported Outcome: Change of function as measured by Hemophilia Activities List (HAL), Daily Activities including Work Productivity and Activity Impairment Scale (WPAI).</measure>
    <time_frame>Baseline and at 36 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Reported Outcome: Change of function as measured by Hemophilia Activities List (HAL), Daily Activities including Work Productivity and Activity Impairment Scale (WPAI).</measure>
    <time_frame>Baseline and at 48 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Reported Outcome: Change of function as measured by Hemophilia Activities List (HAL), Daily Activities including Work Productivity and Activity Impairment Scale (WPAI).</measure>
    <time_frame>Baseline and at 60 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Reported Outcome: Change of Quality of Life as measured by EuroQol-5 Dimension questionnaire 5 Level (EQ5D), Short Form Health Survey (SF-12), Hemophilia Quality of Life Measure for Adults (HAEMO-QoL-A)</measure>
    <time_frame>Baseline and at 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Reported Outcome: Change of Quality of Life as measured by EuroQol-5 Dimension questionnaire 5 Level (EQ5D), Short Form Health Survey (SF-12), Hemophilia Quality of Life Measure for Adults (HAEMO-QoL-A)</measure>
    <time_frame>Baseline and at 24 months</time_frame>
    <description>Resources: Hospital and Healthcare professional visits</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Reported Outcome: Change of Quality of Life as measured by EuroQol-5 Dimension questionnaire 5 Level (EQ5D), Short Form Health Survey (SF-12), Hemophilia Quality of Life Measure for Adults (HAEMO-QoL-A)</measure>
    <time_frame>Baseline and at 36 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Reported Outcome: Change of Quality of Life as measured by EuroQol-5 Dimension questionnaire 5 Level (EQ5D), Short Form Health Survey (SF-12), Hemophilia Quality of Life Measure for Adults (HAEMO-QoL-A)</measure>
    <time_frame>Baseline and at 48 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Reported Outcome: Change of Quality of Life as measured by EuroQol-5 Dimension questionnaire 5 Level (EQ5D), Short Form Health Survey (SF-12), Hemophilia Quality of Life Measure for Adults (HAEMO-QoL-A)</measure>
    <time_frame>Baseline and at 60 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Reported Outcome: Change of treatment patterns as measured by Hemophilia Treatment Satisfaction Questionnaire (Hemo-SAT) and Validated Hemophilia Regimen Treatment Adherence Scale (Veritas Pro/PRN)</measure>
    <time_frame>Baseline and at 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Reported Outcome: Change of treatment patterns as measured by Hemophilia Treatment Satisfaction Questionnaire (Hemo-SAT) and Validated Hemophilia Regimen Treatment Adherence Scale (Veritas Pro/PRN)</measure>
    <time_frame>Baseline and at 24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Reported Outcome: Change of treatment patterns as measured by Hemophilia Treatment Satisfaction Questionnaire (Hemo-SAT) and Validated Hemophilia Regimen Treatment Adherence Scale (Veritas Pro/PRN)</measure>
    <time_frame>Baseline and at 36 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Reported Outcome: Change of treatment patterns as measured by Hemophilia Treatment Satisfaction Questionnaire (Hemo-SAT) and Validated Hemophilia Regimen Treatment Adherence Scale (Veritas Pro/PRN)</measure>
    <time_frame>Baseline and at 48 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Reported Outcome: Change of treatment patterns as measured by Hemophilia Treatment Satisfaction Questionnaire (Hemo-SAT) and Validated Hemophilia Regimen Treatment Adherence Scale (Veritas Pro/PRN)</measure>
    <time_frame>Baseline and at 60 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Reported outcome: Change of adherence as measured by and Validated Hemophilia Regimen Treatment Adherence Scale (Veritas Pro/PRN)</measure>
    <time_frame>Baseline and at 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Reported outcome: Change of adherence as measured by and Validated Hemophilia Regimen Treatment Adherence Scale (Veritas Pro/PRN)</measure>
    <time_frame>Baseline and at 24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Reported outcome: Change of adherence as measured by and Validated Hemophilia Regimen Treatment Adherence Scale (Veritas Pro/PRN)</measure>
    <time_frame>Baseline and at 36 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Reported outcome: Change of adherence as measured by and Validated Hemophilia Regimen Treatment Adherence Scale (Veritas Pro/PRN)</measure>
    <time_frame>Baseline and at 48 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Reported outcome: Change of adherence as measured by and Validated Hemophilia Regimen Treatment Adherence Scale (Veritas Pro/PRN)</measure>
    <time_frame>Baseline and at 60 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Reported outcome: Change of satisfaction as measured by Hemophilia Treatment Satisfaction Questionnaire (Hemo-SAT)</measure>
    <time_frame>Baseline and at 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Reported outcome: Change of satisfaction as measured by Hemophilia Treatment Satisfaction Questionnaire (Hemo-SAT)</measure>
    <time_frame>Baseline and at 24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Reported outcome: Change of satisfaction as measured by Hemophilia Treatment Satisfaction Questionnaire (Hemo-SAT)</measure>
    <time_frame>Baseline and at 36 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Reported outcome: Change of satisfaction as measured by Hemophilia Treatment Satisfaction Questionnaire (Hemo-SAT)</measure>
    <time_frame>Baseline and at 48 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Reported outcome: Change of satisfaction as measured by Hemophilia Treatment Satisfaction Questionnaire (Hemo-SAT)</measure>
    <time_frame>Baseline and at 60 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Reported outcome: Change of pain as measured by Brief Pain Inventory (Short Form) (BPI-SF)</measure>
    <time_frame>Baseline and at 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Reported outcome: Change of pain as measured by Brief Pain Inventory (BPI-SF)</measure>
    <time_frame>Baseline and at 24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Reported outcome: Change of pain as measured by Brief Pain Inventory (BPI-SF)</measure>
    <time_frame>Baseline and at 36 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Reported outcome: Change of pain as measured by Brief Pain Inventory (BPI-SF)</measure>
    <time_frame>Baseline and at 48 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Reported outcome: Change of pain as measured by Brief Pain Inventory (BPI-SF)</measure>
    <time_frame>Baseline and at 60 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Reported outcome: Change of number of resource utilization as evaluated from the patient perspective</measure>
    <time_frame>Baseline and at 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Reported outcome: Change of number of resource utilization as evaluated from the patient perspective</measure>
    <time_frame>Baseline and at 24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Reported outcome: Change of number of resource utilization as evaluated from the patient perspective</measure>
    <time_frame>Baseline and at 36 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Reported outcome: Change of number of resource utilization as evaluated from the patient perspective</measure>
    <time_frame>Baseline and at 48 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Reported outcome: Change of number of resource utilization as evaluated from the patient perspective</measure>
    <time_frame>Baseline and at 60 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Reported outcome: Change of well-being as measured by Psychological General Well Being Schedule (PGWBI) as well as Smoking and drinking behavior and recreational drug use</measure>
    <time_frame>Baseline and at 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Reported outcome: Change of well-being as measured by Psychological General Well Being Schedule (PGWBI) as well as Smoking and drinking behavior and recreational drug use</measure>
    <time_frame>Baseline and at 24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Reported outcome: Change of well-being as measured by Psychological General Well Being Schedule (PGWBI) as well as Smoking and drinking behavior and recreational drug use</measure>
    <time_frame>Baseline and at 36 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Reported outcome: Change of well-being as measured by Psychological General Well Being Schedule (PGWBI) as well as Smoking and drinking behavior and recreational drug use</measure>
    <time_frame>Baseline and at 48 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Reported outcome: Change of well-being as measured by Psychological General Well Being Schedule (PGWBI) as well as Smoking and drinking behavior and recreational drug use</measure>
    <time_frame>Baseline and at 60 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Outcome: Change of Hemophilia A status</measure>
    <time_frame>Baseline and every 12 months up to 60 months</time_frame>
    <description>Hemophilia A status as defined by: - Last measured FVIII level - History of intracranial hemorrhage and age of occurrence - Number of Bleeding episodes/events in the last year - Location of bleed - Confirmed microbleeds on past imaging - PK assessment (if available): Name of FVIII product for most recent PK evaluation - Dose of Factor VIII product administered for most recent PK evaluation - Measured Factor VIII level - Factor VIII half-life and time point of measurement -- Central Venous Access Device (CVAD) or AV (arterial-venous) fistulae</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Outcome: Change of Joint Status</measure>
    <time_frame>Baseline and every 12 months up to 60 months</time_frame>
    <description>Joint Status as defined by: - Hemophilia Joint Health Score/ Pettersson Additive Scale - Range of motion - Imaging (where available) - Target joints and past surgical procedures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Outcome: Baseline disease characteristics</measure>
    <time_frame>Baseline</time_frame>
    <description>Baseline disease characteristics and disease course as defined by: - Date of diagnosis of Hemophilia A - Age at first treatment with factor replacement therapy (child/adult) - Type of factor VIII gene mutation (if available) - Factor VIII level at initial diagnosis (if available) - History of inhibitor and assay used for detection - Date of determination of peak level of inhibitor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Outcome: Change of treatment patterns including Hemophilia treatments via patient chart</measure>
    <time_frame>Baseline and every 12 months up to 60 months</time_frame>
    <description>Treatment patterns as measured by: - Treatment choice and dose (Factor VIII use and type) - Treatment Regimen - Immune tolerance therapy - Products for inhibitors - Blood bank products - Non plasma and topical products</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">272</enrollment>
  <condition>Hemophilia A</condition>
  <arm_group>
    <arm_group_label>Patients with moderate to severe Hemophilia A / Cohort 1</arm_group_label>
    <description>Patients aged over 16 years, with documented physician-confirmed diagnosis of moderate or severe Hemophilia A (severity defined as moderate = FVIII activity 1% to 5% and severe = FVIII activity ≤1%)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Available Recombinant, and Human Factor VIII products incl. Kogenate FS (Recombinant Factor VIII, BAY14-2222)</intervention_name>
    <description>Recombinant and Human Factor VIII / Used on demand or prophylaxis of bleeds</description>
    <arm_group_label>Patients with moderate to severe Hemophilia A / Cohort 1</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients aged over 16 years, with documented physician-confirmed diagnosis of moderate or
        severe Hemophilia A (severity defined as moderate = FVIII activity 1% to 5% and severe =
        FVIII activity ≤1%)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 16 or over.

          -  Have documentation of physician-confirmed diagnosis of moderate or severe Hemophilia A
             (severity defined as moderate = FVIII activity 1% to 5% and severe = FVIII activity
             ≤1%).

          -  Signed written informed consent provided by the patient or the patient's parents for
             patients under the age of 18 (dependent of local regulations).

          -  Signed written assent is also required for patients under the age 18 years (dependent
             on local regulations).

          -  Plan to receive at least half of their Hemophilia care at the registry site.

          -  Willing and able to enter data as per the data collection schedule.

          -  Currently receiving prophylactic or on demand treatment (including within last 6months
             for on demand).

          -  Expected life expectancy of at least 2 years.

        Exclusion Criteria:

          -  Patients with Hemophilia B

          -  Patients with von Willebrand disease (vWD)

          -  Patients with other rare bleeding disorders

          -  Unable to comply with the study protocol
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
    <country>China</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Taiwan</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2015</study_first_submitted>
  <study_first_submitted_qc>March 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2015</study_first_posted>
  <last_update_submitted>April 10, 2018</last_update_submitted>
  <last_update_submitted_qc>April 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

